Pancreatic Cancer Research

ResearcherHumboldt-Universität zu BerlinActive in the last 2 years

Lea Timmermann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0122-7744; OpenAlex author ID A5043350538. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
75
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. Virtual reality volumetric rendering versus cross-sectional imaging for pancreatic cancer resectability assessment: a pilot randomized controlled reader study. Co-author DOI 10.1186/s42234-026-00202-2↗
  2. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  3. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  4. Correction: Felsenstein M. et al. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? J. Clin. Med. 2022… Co-author DOI 10.3390/jcm12216947↗
  5. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? Co-author DOI 10.3390/jcm11092367↗
  6. Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection? First author DOI 10.3390/medicina57010077↗
  7. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis. Co-author DOI 10.21873/anticanres.13781↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thomas Malinka · 7 shared papers, 2019–2026 · strength 1.02
  2. Matthäus Felsenstein · 3 shared papers, 2022–2026 · strength 0.54
  3. Uli Fehrenbach · 3 shared papers, 2022–2026 · strength 0.54
  4. Uwe Pelzer · 4 shared papers, 2019–2023 · strength 0.54
  5. Christian Benzing · 2 shared papers, 2022–2023 · strength 0.28
  6. Bruno Valentin Sinn · 2 shared papers, 2022–2023 · strength 0.28
  7. Mengwen Hu · 2 shared papers, 2022–2023 · strength 0.28
  8. Moritz Queisner · 1 shared paper, 2026 · strength 0.26
  9. Karl Eisenträger · 1 shared paper, 2026 · strength 0.26
  10. Benjamin Struecker · 1 shared paper, 2026 · strength 0.26
  11. Marcus Bahra · 2 shared papers, 2019–2021 · strength 0.25
  12. Fritz Klein · 2 shared papers, 2019–2021 · strength 0.25
  13. Nathalie Rosumeck · 2 shared papers, 2019–2021 · strength 0.25
  14. Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.12
  15. Raëf Abdallah · 1 shared paper, 2023 · strength 0.12
  16. Jin‐Young Jang · 1 shared paper, 2023 · strength 0.12
  17. Giuseppe Malleo · 1 shared paper, 2023 · strength 0.12
  18. Gregory C. Wilson · 1 shared paper, 2023 · strength 0.12
  19. Ryan K. Schmocker · 1 shared paper, 2023 · strength 0.12
  20. Jin Peng He · 1 shared paper, 2023 · strength 0.12
  21. Sarah Maloney · 1 shared paper, 2023 · strength 0.12
  22. Russell F. Palm · 1 shared paper, 2023 · strength 0.12
  23. John Bart Rose · 1 shared paper, 2023 · strength 0.12
  24. Yoo Jin Choi · 1 shared paper, 2023 · strength 0.12
  25. Hongbeom Kim · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.